Scilex Holding Company Announces the U.S. Patent and Trademark Office Will Be Issuing New ELYXYB® Patent Related to the Treatment of Acute Pain

Core Insights - Scilex Holding Company announced that the U.S. Patent and Trademark Office will issue a new patent related to the treatment of acute pain, further strengthening its intellectual property for ELYXYB®, an FDA-approved oral solution for acute migraine treatment, expected in late 2024 [1][2] Company Overview - Scilex is focused on acquiring, developing, and commercializing non-opioid pain management products for acute and chronic pain, targeting high unmet needs and large market opportunities [4][6] - The company’s commercial products include ZTlido®, ELYXYB®, and Gloperba®, with ELYXYB® being the only FDA-approved ready-to-use oral solution for acute migraine treatment [4][5] Market Potential - The U.S. oral migraine drug market was estimated at $1.8 billion in 2022, while the total acute pain market was approximately $3 billion in 2021 [1][4] - There are about 100 million cases of acute pain in the U.S., indicating a significant market opportunity for non-opioid therapies [1][4] Product Efficacy - ELYXYB® has shown rapid pain relief in clinical studies, with patients experiencing relief in as little as 15 minutes and significant pain relief compared to placebo within 45 minutes in about 50% of patients [2][4] - The product is positioned as a first-line non-opioid therapeutic alternative to opioids and acetaminophen, which are associated with risks such as acute liver failure [1][2] Future Developments - The new patent will enable Scilex to file future applications for acute pain treatments, enhancing its product portfolio and market presence [2][4]